OakChart

Verrica Pharmaceuticals Inc

VRCAHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

3.91+0.39 (11.08%)
2026-11-12 05:19 CET
Market cap
67.17 USD m
Revenue, TTM
30.32 USD m
Net income, TTM
-31.18 USD m
Free cash flow, TTM
-13.46 USD m
EPS diluted, TTM
-1.67
P/E
-
Compare

Price

VRCA against its 20, 50 and 200-day averages
2050200missearnings
4.006.008.00267K534KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26VRCAclose 3.9120-day 3.4850-day 4.13200-day 5.443.9152w low

60.2% under the 52-week high of 9.82 on 28 Nov 2025. 52-week low 3.08 on 5 Nov 2026. Last 15 sessions, 35.4% high to low

Volume 0.95× normal · the line is the 50-bar volume average

Profile

VRCA
52-week range, 12% of the way up
3.089.82

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Employees76
IPOJun 15, 2018
Beta1.66
ATR, 14d0.32
Rel volume0.95
Short float2.79%
Insider own49.00%
Inst own27.06%

Snapshot

6 groups

Valuation

Index-
Market Cap67.17M
Enterprise Value57.78M
Income-31.18M
Sales30.32M
Book/sh0.25
Cash/sh0.65
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees76
IPOJun 15, 2018

Ratios

P/E-
Forward P/E-
PEG-
P/S2.22
P/B15.60
P/C6.00
P/FCF-
EV/EBITDA-
EV/Sales1.91
Quick Ratio1.21
Current Ratio1.33
Debt/Eq0.42
LT Debt/Eq0.20
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.67
EPS next Y-1.34
EPS next Q-0.50
EPS this Y-21.69%
EPS next Y34.55%
EPS next 5Y8.78%
EPS past 3/5Y38.35% 37.12%
Sales past 3/5Y57.93% -
EPS Y/Y TTM79.84%
Sales Y/Y TTM106.21%
EPS Q/Q-2971.63%
Sales Q/Q-53.85%
EarningsNov 12 AMC
EPS/Sales Surpr.-60.00% 2.24%

Ownership

Insider Own49.00%
Insider Trans0.50%
Inst Own27.06%
Inst Trans-0.75%
ROA-83.02%
ROE-240.35%
ROIC-604.20%
Gross Margin85.89%
Oper. Margin-87.18%
Profit Margin-102.84%
SMA2012.24%
SMA50-5.36%
SMA200-28.14%
Trades-

Technical

Shs Outstand17.18M
Shs Float8.76M
Short Float2.79%
Short Ratio3.40
Short Interest0.24M
52W High9.82 -60.19%
52W Low3.08 26.95%
Volatility10.42% 9.07%
ATR (14)0.32
RSI (14)55.01
Beta1.66
Rel Volume0.95
Avg Volume71.79K
Volume68,232

Performance

Perf Week13.17%
Perf Month9.22%
Perf Quarter-19.55%
Perf Half Y-46.95%
Perf YTD-52.95%
Perf Year6.83%
Perf 3Y-87.28%
Perf 5Y-96.89%
Perf 10Y-
Recom1.29
Target Price13.83
Prev Close3.52
Price3.91
Change %11.08%

Analyst ratings

latest 10 of 15
DateActionAnalystRating changeTargetImplied
Aug 27, 2026InitiatedLLake StreetBuy$9+130.2%
May 26, 2026ResumedHH.C. WainwrightBuy$12+206.9%
Nov 06, 2024DowngradeHH.C. WainwrightBuy → Neutral
Nov 05, 2024DowngradeRRBC Capital MktsOutperform → Sector Perform
Jul 25, 2023UpgradeNNeedhamHold → Buy$10+155.8%
Mar 22, 2023InitiatedJJefferiesBuy$10+155.8%
Feb 13, 2023UpgradeRRBC Capital MktsSector Perform → Outperform$4 → $11+181.3%
May 25, 2022DowngradeRRBC Capital MktsOutperform → Sector Perform$16 → $4+2.3%
May 14, 2021InitiatedRRBC Capital MktsOutperform$19+385.9%
Dec 24, 2020ReiteratedHH.C. WainwrightBuy$18 → $21+437.1%

Peers

Mkt cap
TickerCompanyMkt cap
PTHSPelthos Therapeutics Inc36.92M
ARQTArcutis Biotherapeutics Inc3.59B
SLGLSol-Gel Technologies Ltd207.57M
DERMJourney Medical Corp125.31M
ACRSAclaris Therapeutics Inc688.38M
EVMNEvommune Inc312.84M
INCYIncyte Corp24.92B
DRMADermata Therapeutics Inc3.54M
EOLSEvolus Inc491.11M
BHCBausch Health Companies Inc3.13B

Insider trading

12 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Zawitz DavidChief Operating OfficerAug 17 '26Buy4.986,00029,88027,000Aug 18 05:00 PM
Rieger JaysonCEO and PresidentAug 14 '26Buy5.0620,000101,200202,593Aug 18 05:00 PM
Rieger JaysonCEO and PresidentAug 17 '26Buy4.915,00024,550207,593Aug 18 05:00 PM
Rosenberg Noah L.CMOAug 17 '26Buy4.914,20020,6226,557Aug 18 05:00 PM
Rosenberg Noah L.CMOAug 18 '26Buy4.922,0309,9888,587Aug 18 05:00 PM
Kirby John J.Interim CFOAug 18 '26Buy4.935,00024,65023,962Aug 18 05:00 PM
Rosenberg Noah L.CMONov 25 '25Buy4.242,35710,0002,357Nov 25 07:00 PM
Kirby John J.Interim CFONov 25 '25Buy4.243,53615,0018,962Nov 25 07:00 PM
Zawitz DavidChief Operating OfficerNov 25 '25Buy4.2410,00042,42521,000Nov 25 07:00 PM
Rieger JaysonCEO and PresidentNov 25 '25Buy4.2494,311400,114182,593Nov 25 07:00 PM
Manning Paul BDirectorNov 25 '25Buy4.242,750,76211,670,1083,348,372Nov 25 07:00 PM
Manning Paul BDirectorNov 25 '25Buy4.241,375,3805,835,0503,958,189Nov 25 07:00 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
AVTMAvantis Total Equity Markets ETFAUM: 758.92M

News

latest 14 of 200
  • Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London (GlobeNewswire)
  • Verrica Must Prove YCANTH Momentum Survived Summer As Shares Slide Toward Lows (Earnings Whispers) -10.56%
  • Verrica Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026 (GlobeNewswire)
  • Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility (GlobeNewswire) +5.51%
  • Verrica Pharmaceuticals to Present New YCANTH Data Analysis at Two Upcoming Dermatology Conferences (GlobeNewswire) +7.51%
  • Verrica Pharmaceuticals to Present YCANTH and VP-315 Data at Two Upcoming Dermatology Conferences (GlobeNewswire)
  • Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
  • Verrica completes enrolment in Phase III trial of Ycanth (Hospital Management) +12.23%
  • Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH for the Treatment of Common Warts, with Topline Data Expected Q1 2027 (GlobeNewswire)
  • Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results (GlobeNewswire) -5.22%
  • Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital (GlobeNewswire)
  • Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026 (GlobeNewswire)
  • Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH for the Treatment of Molluscum Contagiosum in Israel (GlobeNewswire)
  • Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH (VP-102) for the Treatment of Common Warts (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-12--0.497--6.205
2026Q22026-08-06-0.620-0.388-0.6205.865.734
2026Q12026-05-12-0.450-0.420-0.4545.024.514
2025Q42026-03-11-0.570-0.703-0.5725.094.524
2025Q32025-11-14-0.030-0.378-0.02914.349.755
2025Q22025-08-120.020-0.9000.02212.704.273
2025Q12025-05-13-1.000-1.262-1.0273.442.546
2024Q42025-03-11-2.400-2.500-2.4070.341.045
2024Q32024-11-04-4.900-3.763-4.884-1.785.265
2024Q22024-08-14-3.700-4.139-3.6965.184.586
2024Q12024-05-13-4.400-4.470-4.3743.832.816
2023Q42024-02-29-5.300-5.620-5.3151.990.985
2023Q32023-11-09-5.400-3.613-5.3832.920.456
2023Q22023-08-08-2.400-2.102-2.3940.180.065
2023Q12023-05-09-1.500-1.905-1.5320.040.324
2022Q42023-03-06-1.400-1.913-1.4440.070.314

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-11.300-12.975-11.3290.000.00
2020FY-17.100-16.100-17.0810.000.00
2021FY-13.000-14.550-12.97112.0012.00
2022FY-7.200-9.143-7.1689.037.42
2023FY-14.800-13.909-14.7755.124.03
2024FY-14.800-14.460-14.7817.578.25
2025FY-1.680-1.527-1.68035.5835.00
2026FY--2.045--24.39
2027FY--1.338--39.22
2028FY--1.275--44.75
2029FY-1.430--158.2
2030FY-1.860--207.65

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-217016.205.307.50
2026Q3S2026-10-207246.205.307.50
2026Q3S2026-08-267246.415.407.50
2026Q3S2026-08-076246.405.407.50
2026Q3S2026-07-276006.845.058.60
2026Q3S2026-06-196226.845.058.60
2026Q3S2026-06-186226.845.058.60
2026Q3S2026-05-256226.845.058.60
2026Q3S2026-05-226226.845.058.60
2026Q3S2026-05-135226.795.058.60
2026Q3S2026-04-155036.795.058.50
2026Q3S2026-03-135036.795.058.50
2026Q3S2026-03-114037.236.408.50
2026Q3S2026-01-313008.007.009.00

Estimate history

EPS, annual-3.798-14.082-11.329-17.081-12.971-7.168-14.775-14.781-1.679-1.6729
Period201720182019202020212022202320242025TTM
EPS, quarterly-3.696-4.884-2.407-1.0270.022-0.029-0.572-0.454-0.617
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000129.0325.1247.56635.57730.32
Period201720182019202020212022202320242025TTM
Sales, quarterly5.177-1.7810.3443.43912.70214.3445.0925.0235.862
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual2.572.572.5792.5442.7524.1094.2419.17817.17917.179
Period201720182019202020212022202320242025MRQ
Shares, quarterly4.2464.569.1789.1799.2559.4917.17917.17917.179
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue30.3235.587.575.129.0312.000.000.000.00
Cost of Goods Sold Incl. D&A4.283.442.741.160.720.470.230.260.02
Gross Profit26.0432.144.833.968.3111.53-0.23-0.26-0.02
Selling, General and Administrative Excl. Other52.4844.0869.7167.1829.6042.4439.9529.8221.86
Research and Development14.628.8611.8420.3012.2015.9315.6715.4412.83
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-26.43-11.94-64.88-63.22-21.30-30.91-40.18-30.08-21.88
Interest Expense3.737.749.413.962.174.293.030.000.00
Unusual Expense1.44-1.113.600.001.44----
Net Income Before Taxes-31.18-17.89-76.58-67.00-24.49-35.08-42.69-28.21-20.65
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-31.18-17.89-76.58-67.00-24.49-35.08-42.69-28.21-20.65
Net Income From Continuing Operations-31.18-17.89-76.58-67.00-24.49-35.08-42.69-28.21-20.65
Net Income-31.18-17.89-76.58-67.00-24.49-35.08-42.69-28.21-20.65
EPS (Recurring)-1.42-1.75-14.29-14.78-6.87-12.97-17.08-11.33-14.08
EPS (Basic, Before Extraordinaries)-1.67-1.68-14.78-14.78-7.17-12.97-17.08-11.33-14.08
EPS (Diluted)-1.67-1.68-14.78-14.78-7.17-12.97-17.08-11.33-14.08
EBITDA-25.66-11.16-63.61-62.39-20.58-30.44-39.95-29.82-21.86
Non-Operating Income (Expense)0.420.681.320.190.420.120.521.871.23
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.513.327.1614.384.996.059.823.332.25
Price To Sales Ratio4.302.494.7964.7710.4020.64---
Gross Margin85.8990.3363.7977.2891.9796.07---
Operating Margin-87.18-33.56-857.53-1,233.84-235.78-257.57---
Net Margin-102.84-50.27-1,012.15-1,307.47-271.11-292.33---
Shares Outstanding17.1817.189.184.244.112.752.542.582.57
Market Capitalization67.1767.1764.25307.91113.01252.07292.83409.74209.49

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue5.865.025.0914.3412.703.440.34-1.78
Cost of Goods Sold Incl. D&A0.880.891.401.110.490.440.620.43
Gross Profit4.984.133.6913.2312.213.00-0.28-2.22
Selling, General and Administrative Excl. Other16.3813.8510.6411.6110.7011.1310.4918.23
Research and Development6.033.862.522.211.852.281.172.40
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-11.40-9.71-6.951.631.51-8.13-10.77-20.44
Interest Expense0.160.161.312.092.132.202.352.38
Unusual Expense1.700.00-0.23-0.03-0.60-0.253.340.26
Net Income Before Taxes-13.15-9.68-8.07-0.270.20-9.74-16.20-22.86
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-13.15-9.68-8.07-0.270.20-9.74-16.20-22.86
Net Income From Continuing Operations-13.15-9.68-8.07-0.270.20-9.74-16.20-22.86
Net Income-13.15-9.68-8.07-0.270.20-9.74-16.20-22.86
EPS (Recurring)-0.56-0.45-0.58-0.03-0.02-1.05-2.06-4.85
EPS (Basic, Before Extraordinaries)-0.62-0.45-0.57-0.030.02-1.03-2.41-4.88
EPS (Diluted)-0.62-0.45-0.57-0.030.02-1.03-2.41-4.88
EBITDA-11.19-9.52-6.761.811.71-7.92-10.52-20.10
Non-Operating Income (Expense)0.110.19-0.040.160.230.340.260.22
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.210.900.690.720.891.030.762.11
Price To Sales Ratio4.303.033.301.333.425.846.237.37
Gross Margin85.0282.3072.4992.2796.1187.29-81.69124.42
Operating Margin-194.46-193.41-136.4111.3411.89-236.41-3,131.691,147.89
Net Margin-224.38-192.75-158.56-1.911.61-283.28-4,709.881,283.55
Shares Outstanding17.1817.1817.189.499.259.189.184.56
Market Capitalization67.1790.8878.8640.7149.0640.5964.2566.12

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments30.1546.3369.5534.2770.3565.4762.0289.818.66
Short Term Receivables5.400.084.420.490.000.000.000.000.00
Inventories2.242.461.020.000.000.000.000.000.00
Other Current Assets2.802.312.544.363.972.182.971.340.42
Total Current Assets40.5851.1877.5339.1274.3367.6564.9891.159.08
Net Property, Plant & Equipment1.862.583.625.335.504.942.200.260.00
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Long-Term Note Receivable-----0.000.41--
Intangible Assets---0.000.000.000.000.000.00
Deferred Tax Assets0.390.48-------
Other Assets4.690.380.450.280.291.571.240.500.00
Total Assets47.5254.6281.6044.7280.1274.1568.8391.919.08
Short Term Debt Incl. Current Port. of LT Debt0.7513.610.700.3041.9435.510.130.000.00
Accounts Payable2.071.902.460.510.840.351.190.960.17
Other Current Liabilities13.6213.5113.862.653.273.612.041.520.45
Total Current Liabilities16.4429.0117.023.4646.0539.483.352.480.62
Long Term Debt0.8932.3344.811.231.471.690.060.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities0.390.48-------
Other Liabilities5.072.650.000.000.000.000.000.000.00
Total Liabilities22.7864.4861.834.6947.5241.173.412.480.62
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.0015.51
Common Equity24.74-9.8619.7640.0332.6032.9965.4289.43-7.04
Total Shareholders Equity24.74-9.8619.7640.0332.6032.9965.4289.438.47
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity24.74-9.8619.7640.0332.6032.9965.4289.438.47
Total Liabilities & Stockholders Equity47.5254.6281.6044.7280.1274.1568.8391.919.08
Book Value Per Share1.44-1.074.669.7411.8512.9725.3734.79-2.74
Tangible Book Value Per Share1.44-1.074.669.7411.8512.9725.3734.79-2.74
Full-Time Employees76711002238291716-
Price to Book Ratio15.60-6.527.282.527.738.886.262.342.34
Return on Assets-35.02-112.44-106.07-39.23-45.48-59.72-35.10-40.89-92.64
Return on Equity-240.35-1,546.58-224.08-67.42-106.97-86.77-36.43-42.18-103.79
Return on Invested Capital-69.79-340.74-103.75-59.35-102.96-123.11-43.08-23.09-52.66
Quick Ratio2.331.684.4911.311.611.7119.3936.8014.75
Current Ratio2.471.764.5511.311.611.7119.3936.8014.75

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-31.18-17.89-76.58-67.00-24.49-35.08-42.69-28.21-20.65
Depreciation0.780.781.270.840.720.470.230.260.02
Other Funds (Non Cash)9.675.6211.2217.726.927.5610.622.271.82
Funds from Operations-20.74-11.48-64.09-48.44-16.85-27.05-31.84-25.68-18.81
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital7.28-6.252.039.86-1.80-0.541.64-1.730.94
Cash from Operating Activities-13.46-17.74-62.07-38.58-18.65-27.58-30.21-27.41-17.87
Capital Expenditures0.000.00-0.03-0.36-0.30-0.88-1.47-0.68-0.28
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.010.000.000.000.000.00-
Purchase or Sale of Investments0.000.000.000.0054.520.09-1.8927.86-79.12
Purchase of Investments0.000.000.000.00-4.49-68.91-71.74-89.85-79.12
Sale Or Maturity of Investments0.000.000.000.0059.0169.0069.85117.72-
Other Uses0.000.000.000.00-0.18-0.20-0.22-1.22-0.50
Other Sources0.000.000.000.00---0.000.00
Cash from Investing Activities0.000.00-0.02-0.3654.04-1.00-3.5825.95-79.89
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock50.0650.0739.7930.1326.9028.680.450.4299.38
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock50.0650.0739.7930.1326.9028.680.450.4299.38
Proceedsfrom Stock Options-0.010.0039.6430.1226.9028.120.000.0099.37
Issuance or Reduction of Debt, Net-40.23-48.20-0.9244.10-43.754.9734.370.000.00
Change in Long Term Debt-40.23-48.20-0.9244.10-43.754.9734.370.000.00
Issuance of Long Term Debt0.000.000.0044.100.004.9734.370.000.00
Reduction of Long Term Debt-40.23-48.20-0.920.00-43.75-0.010.000.000.00
Net Financing Active Other Cash Flow-0.31-0.310.00-0.02-0.020.000.410.000.00
Other Financing Activities Uses-0.31-0.310.00-0.02-0.02--0.000.00
Cash from Financing Activities9.521.5538.8774.21-16.8733.6535.230.4299.38
Net Change in Cash-3.94-16.18-23.2235.2718.525.071.45-1.031.61
Free Cash Flow-13.46-17.74-62.09-38.94-18.95-28.46-31.68-28.09-18.15
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments11.2020.6030.1521.1015.4029.59
Short Term Receivables11.097.815.407.3317.375.65
Inventories2.711.972.242.302.522.46
Other Current Assets4.922.372.803.591.491.77
Total Current Assets29.9232.7640.5834.3236.7839.47
Net Property, Plant & Equipment2.031.661.861.891.952.33
Total Investments and Advances0.260.260.000.000.000.00
Deferred Tax Assets--0.39---
Other Assets3.804.104.694.690.380.38
Total Assets36.0238.7947.5240.9039.1142.18
Short Term Debt Incl. Current Port. of LT Debt0.960.740.7513.1613.3213.47
Accounts Payable1.602.192.071.582.321.44
Other Current Liabilities19.8813.2813.6214.1613.5814.48
Total Current Liabilities22.4416.2216.4428.9129.2229.40
Long Term Debt0.850.700.8922.5825.5728.96
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--0.39---
Other Liabilities8.415.815.076.451.802.39
Total Liabilities31.7122.7322.7857.9456.5960.75
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity4.3116.0524.74-17.04-17.48-18.58
Total Shareholders Equity4.3116.0524.74-17.04-17.48-18.58
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity4.3116.0524.74-17.04-17.48-18.58
Total Liabilities & Stockholders Equity36.0238.7947.5240.9039.1142.18
Book Value Per Share0.250.931.44-1.80-1.89-2.02
Tangible Book Value Per Share0.250.931.44-1.80-1.89-2.02
Full-Time Employees--76---
Price to Book Ratio15.603.67-4.63-2.28-2.81-2.19
Return on Assets-83.02-44.03-35.02-70.48-106.68-121.65
Return on Equity---240.35---
Return on Invested Capital-254.85-57.79-31.50-4.952.52-93.78
Quick Ratio1.211.902.331.111.171.26
Current Ratio1.332.022.471.191.261.34

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-13.15-9.68-8.07-0.270.20-9.74
Depreciation0.210.190.190.180.200.21
Other Funds (Non Cash)4.312.351.181.841.161.44
Funds from Operations-8.64-7.14-6.711.751.56-8.09
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.64-2.022.017.93-11.61-4.59
Cash from Operating Activities-9.28-9.16-4.709.69-10.04-12.68
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.00-0.0150.070.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.00-0.0150.070.000.000.00
Proceedsfrom Stock Options0.00-0.010.000.000.000.00
Issuance or Reduction of Debt, Net-0.13-0.11-36.01-3.98-4.16-4.06
Change in Long Term Debt-0.13-0.11-36.01-3.98-4.16-4.06
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.13-0.11-36.01-3.98-4.16-4.06
Net Financing Active Other Cash Flow0.000.00-0.310.000.000.00
Other Financing Activities Uses0.000.00-0.310.000.000.00
Cash from Financing Activities-0.13-0.1213.75-3.98-4.16-4.06
Net Change in Cash-9.40-9.289.055.70-14.20-16.73
Free Cash Flow-9.28-9.16-4.709.69-10.04-12.68

Revenue breakdown

License And Collaboration2024: 992.00K 2025: 20.29M
Product2024: 6.57M 2025: 15.29M
United States2024: 7.57M 2025: 35.58M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.79%0.2M8.8M69.08K
2026-10-152.20%0.2M8.8M65.24K
2026-09-302.24%0.2M8.8M62.01K
2026-09-152.31%0.2M8.8M62.71K
2026-08-312.54%0.2M8.8M60.67K
2026-08-143.07%0.3M8.8M40.90K
2026-07-313.27%0.3M8.8M51.88K
2026-07-153.59%0.3M8.8M61.59K
2026-06-303.69%0.3M8.8M71.05K
2026-06-154.00%0.4M8.8M84.68K
2026-05-294.31%0.4M8.8M103.81K
2026-05-154.69%0.4M8.8M114.04K
2026-04-306.79%0.6M8.6M121.31K
2026-04-157.00%0.6M8.3M130.95K
2026-03-3148.80%0.5M1.0M142.90K
2026-03-1346.92%0.5M1.0M161.36K
2026-02-2742.63%0.4M1.0M221.05K
2026-02-1340.48%0.4M1.0M248.42K
2026-01-3025.04%0.3M1.4M232.43K
2026-01-1522.15%0.3M1.4M277.22K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.000.505.000.000.0000.000.000.974-0.0120.000
call2.000.104.900.000.0000.000.000.925-0.0190.001
call3.000.004.900.000.0000.000.000.0000.0000.000
call4.000.004.900.000.0000.000.000.0000.0000.000
call5.000.004.902.100.0002.000.000.987-0.0320.000
call6.000.004.900.000.0000.000.000.848-0.1150.001
call7.000.004.900.000.0000.000.000.828-0.1230.001
call8.000.004.900.000.0000.000.000.843-0.1250.001
call9.000.005.000.008.0070.000.000.482-0.1100.002
put1.000.000.050.055.87820.000.00-0.026-0.0120.000
put2.000.000.100.100.00074.000.000.0000.0000.000
put3.000.004.500.000.0000.000.000.0000.0000.000
put4.000.004.700.650.0003.000.000.0000.0000.000
put5.000.004.901.0029.5482.000.00-0.012-0.0320.000
put6.000.104.900.0015.4950.000.00-0.152-0.1250.001
put7.001.005.500.0013.5620.000.00-0.218-0.1370.002
put8.002.006.500.0014.0350.000.00-0.222-0.1430.002
put9.003.007.500.0014.4390.000.00-0.518-0.1090.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-08-184Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-094Statement of changes in beneficial ownership of securities2026-06-05SEC
2026-06-098-KCurrent report2026-06-05SEC
2026-05-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-12S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-05-128-KCurrent report2026-05-12SEC
2026-04-20ARSAnnual report to security holders. 2025-12-31SEC
2026-04-20DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-20DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-05SEC
2026-03-1110-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-118-KCurrent report2026-03-11SEC
2026-02-17SCHEDULE 13G/ASEC
2026-02-023/A2025-11-25SEC
2026-01-29SCHEDULE 13G/ASEC
2026-01-263Initial statement of beneficial ownership of securities2025-11-25SEC
2025-12-304Statement of changes in beneficial ownership of securities2025-12-23SEC
2025-12-308-KCurrent report2025-12-23SEC
2025-12-30SCHEDULE 13D/ASEC
2025-12-303Initial statement of beneficial ownership of securities2025-12-26SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-08210.89K600
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-1117.97M600

Institutional holders

Manager% owned
Caligan Partners LP5.38%
CANNELL CAPITAL LLC4.56%
Affinity Asset Advisors, LLC4.12%
Velan Capital Investment Management LP2.75%
ARMISTICE CAPITAL, LLC2.48%
BOOTHBAY FUND MANAGEMENT, LLC1.63%
VANGUARD CAPITAL MANAGEMENT LLC1.63%
Mariner, LLC1.21%
GEODE CAPITAL MANAGEMENT, LLC0.75%
BlackRock, Inc.0.43%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND0.83%
VANGUARD EXTENDED MARKET INDEX FUND0.79%
Fidelity Extended Market Index Fund0.35%
iShares Micro-Cap ETF0.20%
Fidelity Total Market Index Fund0.12%
Fidelity Series Total Market Index Fund0.11%
Fidelity Nasdaq Composite Index Fund0.07%
Dimensional U.S. Small Cap ETF0.04%
1290 VT Micro Cap Portfolio0.01%
U.S. MICRO CAP PORTFOLIO0.01%

OakChart. VRCA. Cached 15 minutes.